PHARMACODYNAMICS AND PATHOLOGICAL PRINCIPLES IN

NURSING CARE

FINAL EXAM
Answer the following comprehensively.
1. At this Pandemic Period, we are aware of the issues of the vaccine in
preventing and controlling this infection. We know that to develop a vaccine
requires a series of experimental trials until it achieved not less than 90%
effectiveness before it can be commercialized and prescribed for application.
Initial application of a vaccine developed showed early mortality among senior
citizens Norway.
As a healthcare provider who also require protection from infection of Covid-19
and its variant, state your position in the application of vaccine to members of the
population. As much as possible, provide empirical support or clinical
observation to strengthen your position.
COVID-19 can have serious, life-threatening complications, and there is no way
to know how COVID-19 will affect you. The arrival of safe, effective COVID-19 vaccines
is a major development in the coronavirus pandemic. We understand that some people
may be concerned about getting vaccinated now that COVID-19 vaccines are available.
While more COVID-19 vaccines are being developed as quickly as possible, routine
processes and procedures remain in place to ensure the safety of any vaccine that is
authorized or approved for use. Even though the coronavirus vaccines were developed
more quickly than other vaccines in the past, they have been carefully tested and
continue to be monitored.
Getting vaccinated yourself may also protect people around you, particularly
people at increased risk for severe illness from COVID-19. When you get vaccinated,
you are protecting yourself and helping to protect the whole community. When enough
people in the community are vaccinated, it slows down the spread of disease.
However, a number of scientific unknowns remain concerning the effectiveness
of COVID-19 vaccines: efficacy in preventing disease and limiting transmission,
including for variants of SARS-CoV-2; duration of protection offered by vaccination;
timing of booster doses; whether vaccination offers protection against asymptomatic
infection; age and population groups that should be prioritized for vaccination, specific
contraindications, how long before travel vaccines should be offered; and possible
exemption of people who have antibodies against SARS-CoV-2.
Safe and effective vaccines will be a gamechanger: but for the foreseeable future
we must continue to observe wearing masks, physical distancing and avoiding crowds.
Being vaccinated does not mean that we can throw caution to the wind and put
ourselves and others at risk, particularly because it is still not clear the degree to which
the vaccines can protect not only against disease but also against infection and
transmission.